RxDoctor Payments Data

Kent Metcalf, DO

Family Medicine · Mt Pleasant, IANPI 1447329313

Payments from drug & device makers

$177in general payments, 2019–2025

Across 4 payments — averaging $44.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$118
  • Novo Nordisk$34
  • Dexcom, Inc.$26

What the payments were for

  • Food & beverage$177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$118
Novo Nordisk2$34
Dexcom, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$177 in reported general payments places this provider in the 55th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$339,123
Medicare patients
648
Services billed
4,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$77,434
JardianceEmpagliflozin57$41,107
OzempicSemaglutide25$26,876
Combivent RespimatIpratropium/Albuterol Sulfate31$20,842
TrulicityDulaglutide15$19,689
Breo ElliptaFluticasone/Vilanterol23$10,391
XareltoRivaroxaban14$8,784
JanuviaSitagliptin Phosphate14$7,462
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$5,379
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,284
Ventolin HfaAlbuterol Sulfate33$3,180
SymbicortBudesonide/Formoterol Fumarate12$2,903
Gabapentin147$2,793
Pregabalin67$2,174
Tamsulosin Hcl117$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$77,434123 claims
Novo NordiskOzempic$34$26,87625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Mt Pleasant

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →